China-Originated Assets Lead Global GLP-1 Deals

Differentiation A Key Consideration

 
• By Xu Hu
  
A blue-colored ball is running ahead.
Fierce domestic R&D competition is driving Chinese firms' differentiated GLP-1 assets but not all developers may be able to strike cross-border deals (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from China